Lindbrook Capital’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$2.66K Buy
280
+30
+12% +$375 ﹤0.01% 2196
2024
Q4
$4.12K Buy
250
+34
+16% +$528 ﹤0.01% 2074
2024
Q3
$3.19K Hold
216
﹤0.01% 2191
2024
Q2
$3K Buy
216
+145
+204% +$2.06K ﹤0.01% 2218
2024
Q1
$1.12K Sell
71
-191
-73% -$2.95K ﹤0.01% 2397
2023
Q4
$4.24K Buy
262
+191
+269% +$3.13K ﹤0.01% 1971
2023
Q3
$873 Hold
71
﹤0.01% 2392
2023
Q2
$1.14K Hold
71
﹤0.01% 2345
2023
Q1
$1.24K Sell
71
-62
-47% -$883 ﹤0.01% 2406
2022
Q4
$1.23K Sell
133
-729
-85% -$6.8K ﹤0.01% 2417
2022
Q3
$7K Buy
862
+283
+49% +$2.81K ﹤0.01% 1500
2022
Q2
$5K Sell
579
-736
-56% -$7.03K ﹤0.01% 1552
2022
Q1
$16K Sell
1,315
-1,155
-47% -$24.3K ﹤0.01% 1104
2021
Q4
$84K Buy
+2,470
New +$96.7K 0.01% 541
2021
Q2
Sell
-250
Closed -$12K 1969
2021
Q1
$12K Buy
250
+150
+150% +$7.81K ﹤0.01% 945
2020
Q4
$5K Buy
100
+70
+233% +$3.16K ﹤0.01% 1198
2020
Q3
$1K Buy
+30
New +$1.11K ﹤0.01% 1599

Other funds holding NEO

Lindbrook Capital's NEO Position: Q1 2025 in Review

Lindbrook Capital increased its NeoGenomics (NEO) stake by 12% in Q1 2025, buying an estimated $375 and bringing the position to 280 shares worth $2.66K. The position accounts for ﹤0.01% of the portfolio, ranked #2196.

Lindbrook Capital first reported a position in NEO in Q3 2020 and has held it in 17 quarters since. The position peaked at $84K in Q4 2021. 256 funds tracked by Wall St. Rank hold NEO as of Q1 2025.

  • Lindbrook Capital held 280 shares of NeoGenomics worth $2.66K as of Q1 2025.
  • Lindbrook Capital bought 30 NeoGenomics shares in Q1 2025, an estimated $375.
  • NeoGenomics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2196 holding.
  • Lindbrook Capital first reported a position in NeoGenomics in Q3 2020 and has held it in 17 quarters since.
  • Lindbrook Capital's NeoGenomics position peaked at $84K in Q4 2021.
  • 256 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.